Welcome!

News Feed Item

Human Reproductive Technologies: Products and Global Markets

LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Human Reproductive Technologies: Products and Global Markets

https://www.reportbuyer.com/product/1923022/Human-Reproductive-Technologies-Products-and-Global-Markets.html

STUDY GOALS AND OBJECTIVES

The objective of the study is to present a comprehensive, up-to-date look at the market for reproductive technologies and products. Markets are divided according to treatment type and indication. The products in some markets are mature, while products in other markets are just beginning to emerge. The report is directed to decision-makers in the various areas of reproductive drugs and technologies, and it provides insight into those arenas for current and future development.

REASONS FOR STUDY

This BCC Research study is presented to increase the awareness of the global reproductive market by identifying pharmaceutical preparations, devices, technologies and important advancements within the industry. The study analyzes the new therapeutics and technologies for reproductive health and it addresses issues and trends affecting the market. Manufacturers of pharmaceutical products, devices and technologies have stepped up discovery, as the engine driving growth in all markets is research and development.

SCOPE OF STUDY

The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies. The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants and investigates pipeline products and technologies.
The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows.

• Infertility market—male and female factors, pharmaceuticals and future advancements.
o IVF.
o Assistive reproductive technologies.
o Fertility diagnostics.
• Contraception—pharmaceuticals and devices.
• Sexual dysfunction—pharmaceuticals and devices.

Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2013, measuring current market size and identifying current and potential market drivers, forecasting for 2018, assessing current and potential competitors and identifying current competitor market shares for the base year of 2013.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC Research report are based on extensive, first-hand interviews with primary executives, product managers and clinical specialists in the area of reproductive health. Random surveying provided information about the use of products and how products are obtained. Background information was obtained from various government and business sources, medical journals, and trade magazines and interviews with doctors. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends in reproductive drugs and technologies in healthcare. Interviews were also used to confirm and/or adjust market size and competitor market share estimates, as well as to formulate market projections.

All market data pertain to the global market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year is 2013; historical data are provided for 2011 and 2012 and forecast data are provided for 2018. Historical, base year and forecast data are provided for each market segment and subsegment. Market share information is provided for each market subsegment for the 2013 base year.

All average annual growth rates are estimated based on the compilation of data, which includes estimated prevalence of conditions, population growth, products in research and development, historical trends, patent expirations and generic competition.

INTENDED AUDIENCE

This report was prepared as a study of the human reproductive technologies marketplace. Information is presented on the human reproductive technologies industry in general, pharmaceuticals and devices, new technology within the market, new and novel drug applications and market-related issues; in many cases actual revenue is given for the period of 2011 and 2012, with projections of trends and compound annual growth rates (CAGRs) from 2013 through 2018.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives. It also will be of interest to biologists and those interested in the field of reproductive technologies.

ANALYST CREDENTIALS

Mary Anne Crandall is a Medical Analyst, specializing in the pharmaceuticals industry for 20 years, currently working on a Ph.D. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry.

REPORT HIGHLIGHTS

The total market for reproductive technologies and products is estimated to achieve revenues of nearly $16.1 billion in 2013. In 2018, the forecasted revenues will likely reach $19.6 billion, demonstrating a compound annual growth rate (CAGR) of 4.1%.

This report provides:

• An overview of the market for human reproductive technologies.
• Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examinations of market sizes in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception, and sexual dysfunction, with a division of markets according to treatment type and indication.
• Evaluations of pipeline products and technologies.
• Patent analysis.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR STUDY 2
SCOPE OF STUDY 2
METHODOLOGY AND INFORMATION SOURCES 3
INTENDED AUDIENCE 3
ANALYST CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018
($ BILLIONS) 7
SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($
BILLIONS) 7

CHAPTER 3 INDUSTRY OVERVIEW 9

STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM 9
MALE 9
FEMALE 10
Neuroendocrine Regulation 13
Menarche 14
Menstruation Cycle 14
PHASES OF SEXUAL RESPONSES 15
TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE
SYSTEMS 15
Male Sexual Response 16
Female Sexual Response 16
NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE
SYSTEM 17
Estrogen 18
Progestogens 18
Testosterone 19
EFFECTS OF AGING 19
ISSUES AND TRENDS OF REPRODUCTIVE HEALTH 21
CONTRACEPTIVE INSURANCE 21
OVER-THE-COUNTER BIRTH CONTROL PILLS 21
PREIMPLANTATION GENETIC DIAGNOSIS 22
DESIGNER BABIES 22
NEW USE FOR CONTRACEPTIVES 24
AGING AND INFERTILITY 25
DEATH BY CONTRACEPTIVE PATCH 26
SEXUAL DYSFUNCTION AND CANCER 27
INFERTILITY AND CANCER 28
Chemotherapy 28
Radiation 29
Prevention Strategies 30
Procreative Alternatives 30
SIGNALING PATHWAY FOR FERTILITY TREATMENT 31
MARKETING TACTICS 31
MALE BIRTH CONTROL 32
MERCHANDISING TARGETING WOMEN 32
COUNTERFEIT PRODUCTS 32
SURPLUS EMBRYOS AND FETUSES 33
STEM CELL AND OTHER CONTROVERSIAL ISSUES - SELECTED
INTERNATIONAL VIEWS 35
CONTROVERSIAL DISPOSAL OF EMBRYOS 39
DEMOGRAPHICS 41
UNITED STATES 41
TABLE 2 U.S. LIVE BIRTH RATES, 1960–2012 (THOUSANDS) 41
FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS) 42
TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL
POPULATION, THROUGH 2030 (THOUSANDS/%) 42
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL
POPULATION, 2003-2030 (%) 42
TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST
YEAR: 2000 AND 2008 (PER 1,000 WOMEN) 43
TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR
FORCE STATUS: 1980–2008 44
TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND
MARITAL STATUS (%) 45
EU 45
TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960–2011 (PER 1,000
POPULATION (%)) 46
ASIA 47

CHAPTER 4 INFERTILITY MARKET 50

INTRODUCTION AND OVERVIEW OF INFERTILITY 50
DEFINITION OF INFERTILITY 50
ETIOLOGY OF INFERTILITY 50
EVALUATION OF FERTILITY 50
Male Factor 51
Artificial Insemination 52
Vaginal and Cervical Factors 55
Immunological Factors 56
Uterine and Tubal Factors 57
Ovarian Factors 58
UNEXPLAINED INFERTILITY 59
MULTIPLE BIRTHS 60
ASIA FACTOR 61

CHAPTER 5 METHODS OF TREATMENT 63

FERTILITY PHARMACEUTICALS 63
INTRODUCTION AND TYPES 63
Antagon 64
Bravelle 65
Cetrotide 65
Clomid 65
Crinone and Prometrium 66
Fertinex 67
Follistim 67
Gonal-F 67
Humegon 68
Lupron 68
Novarel 68
Ovidrel 69
Parlodel 69
Pregnyl 69
Profasi 69
Prometrium 69
Repronex 69
Serophene 70
TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70
MARKET REVENUES AND FORECAST 71
TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S.
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 71
FUTURE ADVANCEMENTS IN INFERTILITY PRODUCTS 72
CORIFOLLITROPIN ALFA INJECTION 72
PROGESTERONE VAGINAL RING 72
XM17 72
TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT 72
COMPETITIVE ANALYSIS 72
TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED
MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%) 73
FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY
REVENUES, 2013 (%) 73

CHAPTER 6 ASSISTIVE REPRODUCTIVE TECHNOLOGIES 75

INTRODUCTION 75
TYPES 75
IVF 75
Ovulation Induction 76
Oocyte Retrieval 76
Intracytoplasmic Sperm Injection (ICSI) 76
Fertilization 77
Embryo Transfer 77
Results of IVF 77
GIFT 78
ZIFT 78
WOMBS FOR RENT 79
OOCYTE DONATION 80
FROZEN EMBRYOS 81
UNITED STATES FERTILITY CLINICS 82
TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011
(U.S.) 82
TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011
(%) 82
TABLE 14 PREGNANCY SUCCESS RATES, 2011 83
INTERNATIONAL FERTILITY CLINICS 84
TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES 84
MARKET REVENUES AND FORECAST 85
TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT
U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 85
FUTURE TRENDS IN ASSISTIVE REPRODUCTIVE TECHNOLOGY 85
COMPETITIVE ANALYSIS 87
TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED
MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 87
FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY
REVENUES, 2013 (%) 87

CHAPTER 7 FERTILITY DIAGNOSTICS 90

INTRODUCTION 90
TYPES 90
Urine Studies 90
Pregnancy Testing 90
Ovulation Testing 91
Sperm Testing 92
Hormone Studies 93
Blood Studies 93
MARKET REVENUES AND FORECAST 94
TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 94
COMPETITIVE ANALYSIS 94
TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 ($ MILLIONS/%) 94
FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 (%) 95
FUTURE ADVANCEMENTS IN DIAGNOSTIC FERTILITY TREATMENT 95
TOTAL INFERTILITY MARKET REVENUES AND FORECAST 96
TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 96
FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 96

CHAPTER 8 CONTRACEPTION MARKET 98

INTRODUCTION AND OVERVIEW OF CONTRACEPTION 98
TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44.,
2011 (THOUSANDS) 100
TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT) 100
PHARMACEUTICALS 101
Types 101
Oral Contraceptives 101
TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES,
2013 103
Alesse 105
Beyaz 105
Brevicon and Norinyl 105
Desogen 105
Estrostep 105
Levlen ED 106
Levora 106
Lo -Loestrin 106
Lo/Ovral 106
Low-Ogestrel 106
Lybrel 106
Microgestin 107
Mircette 107
Natazia 107
Necon 107
Nordette 107
Nor-QD 107
Ortho Evra 108
Ortho Micronor 108
Ortho Tri-Cyclen 108
OrthoCept 108
Ovcon 35 109
Ovral 109
Quartette 109
Safyral 109
Seasonale 109
Tri-Levlen 110
Tri-Norinyl 110
Triphasil 110
Trivora 110
Yasmin 28 110
Zovia 111
Zoely 111
TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH
CONTROL PILLS 111
TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS 113
TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO 113
OTHER DRUG REGIMENS FOR CONTRACEPTION 114
Depo-Provera 114
Plan B One Step 114
Mifeprex 115
MARKET REVENUES AND FORECAST 115
TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 116
COMPETITIVE ANALYSIS 116
TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 116
FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 116
PRESCRIPTION DEVICES 117
INTRODUCTION AND TYPES 117
Intrauterine Devices 118
NuvaRing 118
Implanon 119
TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013 119
MARKET REVENUES AND FORECAST 119
TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 120
COMPETITIVE ANALYSIS 120
TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 120
FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 (%) 120
FUTURE ADVANCEMENTS IN CONTRACEPTION 121
TABLE 32 CONTRACEPTIVES IN DEVELOPMENT 121
AG-200-15 122
ARC 122
C31G (SAVVY) 122
FC PATCH 122
LECETTE 122
AG890 123
USHERCELL 123
LEVOSERT IUD 123
TOTAL MARKET REVENUES AND FORECAST 123
TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 123
FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 124

CHAPTER 9 SEXUAL DYSFUNCTION MARKET 126

INTRODUCTION AND OVERVIEW 126
TYPES OF SEXUAL DYSFUNCTION 126
CAUSES OF SEXUAL DYSFUNCTION 127
DEMOGRAPHICS OF SEXUAL DYSFUNCTION 127
PHARMACEUTICALS 128
Introduction and Types 128
Viagra 128
Cialis 128
Levitra 128
Staxyn 129
Stendra/Spendra 129
Yohimbine 129
Caverject 129
MUSE 129
TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS 130
MARKET REVENUES AND FORECAST 130
TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 131
COMPETITIVE ANALYSIS 131
TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 131
FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 (%) 131
DEVICES 132
Introduction and Types 132
SomaTherapy-ED SOMAerect Stf 132
Viberect 133
Erectaid Classic System 133
AMS Inflatable Penile Implant 134
Coloplast Titan OTR 134
TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS 134
MARKET REVENUES AND FORECAST 134
TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 135
COMPETITIVE ANALYSIS 135
TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 135
FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 135
FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION 136
TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT 136
Flibanserin 137
Femprox 137
LibiGel 137
Lybrido and Lybridos 137
Tefina 138
Topiglan 138
Zoraxel 138
Zydena (udenafil) 138
TOTAL MARKET REVENUES AND FORECAST 138
TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 139
FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 139

CHAPTER 10 PATENTS 141

PATENT ANALYSIS BY MANUFACTURER 141
TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS
AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT 141
PATENTS BY APPLICATION 141
INFERTILITY TREATMENTS 141
CONTRACEPTION 142
SEXUAL DYSFUNCTION 142

CHAPTER 11 LEADING MARKET MANUFACTURERS 144

TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT
MANUFACTURERS, 1976–PRESENT 144

CHAPTER 12 TOTAL MARKET 147

TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($
BILLIONS)
147
TOTAL GLOBAL MARKET FOR REPRODUCTIVE TECHNOLOGIES AND PRODUCTS
BY REGION 147
TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%) 148
FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%) 148
TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%) 149
FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%) 149
TOTAL MARKET SIZE BY CATEGORY 149
TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
THROUGH 2018 ($ MILLIONS)
150
FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
2011–2018 ($ MILLIONS)
150
TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER
OF MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY
MARKET SEGMENT, 2013 ($ MILLIONS/%)
151
FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013 151
FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%) 151
INDUSTRY PARTICIPANTS BY CATEGORY 152
TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY 152
TOTAL MARKET SIZE BY PRODUCT TYPE 154
TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 154
FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011–2018 ($ MILLIONS) 155

CHAPTER 13 PARTICIPATING COMPANIES 157

COMPANY PROFILES 157
ACTAVIS, INC 157
BAYER AG 157
BRISTOL-MYERS SQUIBB CO. 159
CHURCH & DWIGHT COMPANY INC. 159
COOPERSURGICAL INC. 159
ELI LILLY & CO. 160
EMD SERONO, INC 160
FERRING PHARMACEUTICALS 161
GLAXOSMITHKLINE PLC 161
JANSSEN PHARMACEUTICAL 162
MERCK INC. 162
NOVARTIS INTERNATIONAL AG 163
PFIZER INC. 163
PRINCETON BIOMEDITECH CORP. 164
QUIDEL CORP 164
VIVUS INC. 165

CHAPTER 14 APPENDIX A 167

SELECTED LIST OF U.S. FERTILITY CLINICS 167
ALABAMA 167
ARIZONA 167
CALIFORNIA 168
COLORADO 169
CONNECTICUT 170
DISTRICT OF COLUMBIA 170
FLORIDA 170
GEORGIA 171
IDAHO 171
ILLINOIS 171
INDIANA 172
KANSAS 173
MAINE 173
MARYLAND 173
MASSACHUSETTS 173
MICHIGAN 174
MINNESOTA 174
MONTANA 174
NEVADA 174
NEW HAMPSHIRE 175
NEW JERSEY 175
NEW YORK 176
NORTH CAROLINA 176
OREGON 176
RHODE ISLAND 177
SOUTH CAROLINA 177
SOUTH DAKOTA 177
TEXAS 177
UTAH 178
VIRGINIA 178
WASHINGTON 178
SELECTED LIST OF FERTILITY CLINICS IN OTHER REGIONS 179
ASIAN FERTILITY CLINICS 179
AUSTRIA 180
Innsbruck 180
Vienna 180
SWITZERLAND 181
Basel 181
Geneva 181
Zurich 182
GERMANY 182
FRANCE 183
Paris 183
ITALY 183
Naples 183
Rome 184
GREAT BRITAIN 184
London 184

CHAPTER 15 APPENDIX B: LIST OF COMPANIES 187

TABLE 51 LIST OF COMPANIES 187

LIST OF TABLES

SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018
($ BILLIONS)
7
TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE
SYSTEMS 15
TABLE 2 U.S. LIVE BIRTH RATES, 1960–2012 (THOUSANDS) 41
TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL
POPULATION, THROUGH 2030 (THOUSANDS/%) 42
TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR:
2000 AND 2008 (PER 1,000 WOMEN) 43
TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR
FORCE STATUS: 1980–2008 44
TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND
MARITAL STATUS (%) 45
TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960–2011 (PER 1,000
POPULATION (%)) 46
TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70
TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S.
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 71
TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT 72
TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED
MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%) 73
TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011
(U.S.) 82
TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011 (%) 82
TABLE 14 PREGNANCY SUCCESS RATES, 2011 83
TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES 84
TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT
U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 85
TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED
MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 87
TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 94
TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 ($ MILLIONS/%) 94
TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 96
TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44.,
2011 (THOUSANDS) 100
TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT) 100
TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES,
2013 103
TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH
CONTROL PILLS 111
TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS 113
TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO 113
TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 116
TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 116
TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013 119
TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 120
TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 120
TABLE 32 CONTRACEPTIVES IN DEVELOPMENT 121
TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 123
TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS 130
TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 131
TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 131
TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS 134
TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 135
TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 135
TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT 136
TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 139
TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS
AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT 141
TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT
MANUFACTURERS, 1976–PRESENT 144
TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($
BILLIONS)
147
TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%) 148
TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%) 149
TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
THROUGH 2018 ($ MILLIONS)
150
TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER OF
MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET
SEGMENT, 2013 ($ MILLIONS/%)
151
TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY 152
TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 154
TABLE 51 LIST OF COMPANIES 187

LIST OF FIGURES

SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($
BILLIONS)
7
FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS) 42
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL
POPULATION, 2003-2030 (%) 42
FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY
REVENUES, 2013 (%) 73
FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY
REVENUES, 2013 (%) 87
FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 (%) 95
FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 96
FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 116
FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 (%) 120
FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 124
FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 (%) 131
FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 135
FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 139
FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%) 148
FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%) 149
FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
2011–2018 ($ MILLIONS)
150
FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013 151
FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%) 151
FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011–2018 ($ MILLIONS) 155

Read the full report:
Human Reproductive Technologies: Products and Global Markets

https://www.reportbuyer.com/product/1923022/Human-Reproductive-Technologies-Products-and-Global-Markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.